| CTSH |
Report |
Revenue |
IN-LINE |
pred ~$5.475B vs. cons $5.487B |
MEDIUM |
| CTSH |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$1.390 vs. cons $1.378 |
MEDIUM |
| CTSH |
Report |
Bookings growth |
BEAT |
pred ~7.0% YoY vs. cons 5.6% YoY |
MEDIUM |
| CTSH |
Guide |
Q3 2026 Revenue |
UNCHANGED |
guide ~$5.66B-$5.72B vs. cons $5.701B |
LOW |
| CTSH |
Guide |
FY2026 Revenue |
UNCHANGED |
guide ~$22.11B-$22.64B vs. cons $22.289B |
LOW |
| CTSH |
Guide |
FY2026 Adjusted Operating Margin |
BETTER |
guide ~16.0%-16.2% vs. cons ~15.94% |
LOW |
| CTSH |
Guide |
FY2026 Adjusted Diluted EPS |
UNCHANGED |
guide ~$5.63-$5.77 vs. cons $5.704 |
LOW |
| CTSH |
Guide |
Demand commentary |
LOWER |
guide: no discretionary-spend acceleration vs. qualitative consensus UNVERIFIED |
LOW |
| CTSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| CTSH |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guidance with continued demand caution should pressure forward estimates and the multiple |
LOW |